Additional file 1 of Opposing roles of CLK SR kinases in controlling HIV-1 gene expression and latency
Creators: name: Dahal, Subha
name: Clayton, Kiera
name: Been, Terek
name: Fernet-Brochu, Raphaële
name: Ocando, Alonso Villasmil
name: Balachandran, Ahalya
name: Poirier, Mikaël
name: Maldonado, Rebecca Kaddis
name: Shkreta, Lulzim
name: Boligan, Kayluz Frias
name: Guvenc, Furkan
name: Rahman, Fariha
name: Branch, Donald
name: Bell, Brendan
name: Chabot, Benoit
name: Gray-Owen, Scott D.
name: Parent, Leslie J.
name: Cochrane, Alan
Publisher: name: figshare
Year: 2022
Subjects: subject: Biophysics
subject: Biochemistry
subject: Microbiology
subject: FOS: Biological sciences
subject: Cell Biology
subject: Genetics
subject: Molecular Biology
subject: Physiology
subject: Immunology
subject: FOS: Clinical medicine
subject: Cancer
subject: 110309 Infectious Diseases
subject: FOS: Health sciences
subject: 60506 Virology

description: Additional file 1: Table S1. Structure and anti-HIV activity of related compounds present in PKIS library. Table S2. shRNA vectors used. Table S3. Primary antibodies used in the study. Figure S1. Effect of SR kinase depletion or inhibition on HIV-1 expression in J-Lat 10.6 cells. a Schematic of HIV-1 provirus present in J-Lat 10-6 cells. b J-Lat 10.6 cells were infected with lentiviruses expressing shRNAs to the SR kinase indicated and transduced cells were selected with puromycin for 72 h. Following selection, prostratin (2.56 µM) was added to induce HIV-1 gene expression and cells harvested after 24 h for western bot analysis of effects on HIV-1 Gag and GFP expression. c, d Cells were treated with DMSO, 1H3 (200 nM), or 2E3 (100 nM) and HIV-1 expression induced with prostratin. After 24 h, cells were analyzed for effects on c HIV-1 protein levels and d RNA accumulation. Data are indicated as mean ± SEM, n = 4 independent experiments, **p ≤ 0.01, and ***p ≤ 0.001. Dotted vertical lines on the blots represent cropping of lanes on the same representative blot to show compound-treated lanes adjacent to DMSO control lanes. Figure S2. Effect of SR kinase depletion or inhibition on HIV-1 MS RNA Splicing. CEM-HIV* were either a infected with shRNA expressing lentiviruses to deplete indicated SR kinases or b treated with CLK inhibitors. 24 h after induction with Dox and prostratin, cells were harvested, RNA isolated, and RT-PCR performed to detect HIV-1 MS RNAs. Shown on the left are representative gels and, on the right, a summary of n &gt; 3 independent samples. Figure S3. HIV-1 TAR and R-U5-Gag transcription profiles in CEM-HIV* cells. CEM-HIV* cells were uninduced (mock), induced with Dox, or Dox + prostratin for 24 h and cells harvested 24 h post-induction for RNA analysis by digital RT-qPCR. Measures of TAR or R-U5-Gag RNA were normalized to ß2M and results expressed as copy number per µg total RNA. Data are indicated as mean ± SD. Figure S4. Effect of SR kinase depletion or compound treatment on SR protein levels. a Depletion of CLK1 or CLK2 differentially affects abundance of select SR proteins. CEM-HIV* cells were infected with shRNA lentivirus against indicated SR kinases and transduced cells selected with puromycin for 72 h. Following selection, Dox + prostratin was added to induce HIV-1 gene expression and cells harvested for western blots. On the left are the representative western blots showing the effect of individual SR kinase knockdown on SR protein levels and on the right is the quantitation of the western blots across three independent experiments. Band intensity was quantified relative to induced shRNA control and normalized to total protein using Bio-Rad ImageLab software. Data are indicated as mean ± SEM, *p ≤ 0.05, **p ≤ 0.01, and ***p ≤ 0.001. Dotted vertical lines on the blots represent cropping of lanes on the same representative blot to show shRNA-target depletion lanes adjacent to shControl lanes. b Primary CD4+ T cells obtained from healthy donors were treated with DMSO or 200 nM 1H3 and cells harvested for western analysis after 3 days. On the left are the representative blots showing expression levels of indicated SR proteins and on the right is the quantitation of n = 3 blots from three independent donor samples. Band intensity was quantified relative to DMSO control and normalized to total protein using Bio-Rad ImageLab software. Data are indicated as mean ± SEM, *p ≤ 0.05. Dotted vertical lines on the blots represent cropping of lanes on the same representative blot to show 1H3-treated lanes adjacent to DMSO-treated lanes. Figure S5. Activation of primary CD4+ T cells changes the expression levels of select SR proteins with different kinetics. (refer Fig. 5). Representative western blots showing the expression of multiple different SR proteins in untreated versus treated/activated CD4+ T cell lysates at 24 h and 48 h post-activation. On the bottom is the quantitation of the blots across at least 3 donors. Band intensity was quantified relative to untreated control and normalized to total protein load using Bio-Rad ImageLab software. Figure S6. Characterization of 1H3, 2E3, and 1C8 as inhibitors of CMGC kinases (a) Nanosyn in vitro kinase profile of the effect of compounds listed in Table S3 on purified kinases [53]. Results are derived from assays with 196 kinases and only results from the subset whose activity was reduced are shown. Blue color indicates &lt; 10% inhibition, yellow indicates &gt; 70% inhibition. b Purified CLK1 was incubated with increasing concentrations of 1C8 and assayed for effect on CLK1 autophosphorylation. Figure S7. Alignment of CLK1-3. Shown is an alignment of human CLK1-3, indicating the high degree of conservation in the kinase C-terminal kinase domain and the variation in the N-terminal arginine-serine rich domain.